From Limitations to Long-Term Survival in HCC: Empowering Patients With Early Diagnosis and Novel Immunotherapy-Based Combination Regimens

Nov 12 2023
Grand Ballroom Salons F-G - Boston Marriott Copley Place
6:30 - 8:30 AM EST

Description

Supported by: AstraZeneca

Organized by: Answers in CME

Presenters:

Ghassan Abou-Alfa, MD, MBA

Amit Singal, MD

Andrea Wilson Woods, MPW

Investigations into novel first-line immunotherapy-based combination regimens for unresectable hepatocellular carcinoma (HCC) have produced new approvals and evidence. In this live in-person event, join Dr. Abou-Alfa and Dr. Singal as they highlight the latest efficacy and safety data for these regimens. Along with a patient advocate, they will discuss practical multidisciplinary strategies for optimizing diagnosis and management so that as clinicians, you can make the most informed treatment decisions possible for patients suffering from this challenging disease.

Learning Objectives:  

  1. Recognize the role of multidisciplinary team in facilitating early diagnosis of hepatocellular carcinoma (HCC)
  2. Describe the clinical evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC
  3. Outline evidence-based multidisciplinary strategies to optimize long-term outcomes for patients with unresectable HCC who are treated with first-line immunotherapy-based combination regimens

CME Hours: Maximum of 1.0 AMA PRA Category 1 Credit

For more information and to register, visit: https://www.answersincme.com/88783203